Format

Send to

Choose Destination
Pathologe. 2016 Nov;37(Suppl 2):175-179.

Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.

Author information

1
Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, 02115, Boston, MA, USA. amullally@partners.org.

Abstract

Chronic myeloproliferative neoplasms (MPN) comprise a spectrum of clonal neoplastic disorders characterized by overproduction of terminally differentiated cells of the myeloid lineage. A common genetic basis for the BCR-ABL-negative MPN disorders was elucidated in 2005 with the identification of the JAK2V617F mutation in the majority of MPN patients. The discovery of JAK2V617F had a dramatic impact on the diagnosis and treatment of MPN. Testing for JAK2 mutations is now included in the World Health Organization (WHO) criteria for the diagnosis of MPN, and in 2011 the oral JAK2 kinase inhibitor ruxolitinib became the first Food and Drug Administration (FDA)-approved drug for the treatment of myelofibrosis. The drug is now also approved in Europe and Canada.

KEYWORDS:

Hematopoiesis; Myelofibrosis; Myeloproliferative neoplasms (MPN); Somatic mutation; Tyrosine kinase

PMID:
27796499
DOI:
10.1007/s00292-016-0240-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center